SCHEMBL4378154

SCHEMBL4378154

Oc1ccc2c(CS)ncnc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.41
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
MAP4K4 O95819 1/20 0.36
TLR8 Q9NR97 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
KMT2A Q03164 1/20 0.34
RET P07949 6/20 0.34
KDR P35968 6/20 0.34
KIF5B P33176 5/20 0.34
ALK Q9UM73 2/20 0.33
GAK O14976 1/20 0.33
RIPK2 O43353 1/20 0.33
STK10 O94804 1/20 0.33
FLT3 P36888 1/20 0.33
JAK3 P52333 1/20 0.33
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453911 0.79 EGFR (0.46) EGFRESR1ESR2MAP4K4TLR8
SCHEMBL4431055 0.76 MAP4K4 (0.54) EGFRESR1ESR2MAP4K4PI4KA
SCHEMBL160405 0.73 PI4KA (0.55) EGFRMAP4K4ALDH1A1MEN1KMT2A
SCHEMBL5465224 0.72 PDE4A (0.53) EGFRESR1ESR2MAP4K4TLR8
SCHEMBL20813449 0.72 EGFR (0.44) EGFRESR1ESR2MAP4K4TLR8
SCHEMBL4420762 0.71 RET (0.43) EGFRESR1ESR2MAP4K4TLR8
SCHEMBL1664490 0.69 RAB9A (0.47) EGFRALDH1A1MEN1KMT2ARET
SCHEMBL4378151 0.68 EGFR (0.41) EGFRESR1ESR2MAP4K4TLR8
SCHEMBL1192531 0.67 PARP1 (0.47) EGFRESR1ESR2MAP4K4ALDH1A1
SCHEMBL30317618 0.67 PARP1 (0.47) EGFRESR1ESR2MAP4K4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR EGFR 500/4885ESR1 4791/4885ESR2 4128/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 EGFR 549/4885ESR1 917/4885ESR2 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.